Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 7/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 12/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 9/20 | 0.65 |
| ▸ | TSHR | P16473 | 4/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.65 |
| ▸ | DRD2 | P14416 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.65 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | DRD3 | P35462 | 2/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.65 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13415520 | 0.84 | ADRB2 (0.57) | ADRB3ADRB2ADRB1TSHRMAPK1 | |
| SCHEMBL14148265 | 0.84 | ADRB2 (0.62) | ADRB3ADRB2ADRB1TSHRMAPK1 | |
| SCHEMBL13375861 | 0.84 | ADRB2 (0.62) | ADRB3ADRB2ADRB1TSHRMAPK1 | |
| SCHEMBL10115622 | 0.84 | ADRB2 (0.62) | ADRB3ADRB2ADRB1TSHRMAPK1 | |
| SCHEMBL11817913 | 0.83 | ADRB2 (0.77) | ADRB3ADRB2ADRB1TSHRMAPK1 | |
| SCHEMBL4430362 | 0.83 | ADRB2 (0.80) | ADRB3ADRB2ADRB1TSHRMAPK1 | |
| SCHEMBL11878468 | 0.82 | MAPT (0.71) | ADRB3ADRB2ADRB1TSHRMAPK1 | |
| SCHEMBL14291374 | 0.82 | ADRB2 (0.54) | ADRB3ADRB2ADRB1TSHRMAPK1 | |
| SCHEMBL11815926 | 0.82 | ADRB2 (0.59) | ADRB3ADRB2ADRB1TSHRMAPK1 | |
| SCHEMBL11818484 | 0.82 | ADRB2 (0.67) | ADRB3ADRB2ADRB1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134006-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687521-B2 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090176833-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-07-09 | — | — | US | disclosed |
| US-7524965-B2 | Dialkylphenyl compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20070249675-A1 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-10-25 | — | — | US | disclosed |
| US-3994974-A | BRONCHODILATORS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137603-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | ADRB3 4/4885ADRB2 1/4885ADRB1 2/4885 |
| US-20090176833-A1 | DIALKYLPHENYL COMPOUNDS HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | ADRB2, ADRB1, ADRA2C | ADRB3 4/4885ADRB2 1/4885ADRB1 2/4885 |
| US-20070249675-A1 | Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity | ADRB2, ADRB1, ADRA2C | ADRB3 4/4885ADRB2 1/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.